source
- Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downRiding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-based dru…Endpoints · 21d ago↗ source
- Catalent to divest UK site; Rottendorf, Evonik announce manufacturing buildsPlus, news about RoslinCT, Novo Nordisk and more. 🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with ...Endpoints · 21d ago↗ source
- HHS plan to speed drug research won’t remove ‘self-inflicted’ delaysU.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?